共 96 条
[1]
Dolecek TA(2012)CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009 Neuro Oncol 14 1-49
[2]
Propp JM(2016)The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary Acta Neuropathol 131 803-820
[3]
Stroup NE(2013)IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis PLoS One 8 e68782-476
[4]
Louis DN(2016)Co-deletion of 1p/19q as prognostic and predictive biomarker for patients in West Bohemia with anaplastic oligodendroglioma Anticancer Res 36 471-2064
[5]
Perry A(2015)MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide re-challenge in progressive glioblastoma: the DIRECTOR trial Clin Cancer Res 21 2057-108
[6]
Reifenberger G(2016)The Role of Molecular Diagnostics in the Management of Patients with Gliomas Curr Treat Options Oncol 17 51-331
[7]
Zou P(2016)Clinical relevance of prognostic and predictive molecular markers in gliomas Adv Tech Stand Neurosurg 43 91-1354
[8]
Xu H(2006)Targeted modulation of MGMT: clinical implication Clin Cancer Res 12 328-52
[9]
Chen P(2000)Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N Engl J Med 343 1350-1003
[10]
Polivka J(2015)Assessing MGMT methylation status and its current impact on treatment in glioblastoma CNS Oncol 4 47-715